There is evidence that p38 MAPK activation plays a role in recruiting CD8 T lymphocytes into the lungs of COPD patients, and a p38 MAPK inhibitor has been shown to be effective in suppressing inflammation in a model of smoking-induced COPD in mice [49,50]. Here, CD8A is linked to chronic obstructive pulmonary disease.